RELA/P65 IS A MOLECULAR TARGET FOR THE IMMUNOSUPPRESSIVE ACTION OF PROTEIN-KINASE-A

被引:178
作者
NEUMANN, M
GRIESHAMMER, T
CHUVPILO, S
KNEITZ, B
LOHOFF, M
SCHIMPL, A
FRANZA, BR
SERFLING, E
机构
[1] UNIV WURZBURG,INST PATHOL,D-97080 WURZBURG,GERMANY
[2] COLD SPRING HARBOR LAB,FREEMAN LAB CANC CELL BIOL,COLD SPRING HARBOR,NY 11724
[3] INST VIROL & IMMUNOBIOL,D-97078 WURZBURG,GERMANY
[4] INST CLIN MICROBIOL,D-91054 ERLANGEN,GERMANY
关键词
IMMUNOSUPPRESSION; NF-KAPPA-B; PROTEIN KINASE A; P65; RELA;
D O I
10.1002/j.1460-2075.1995.tb07191.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Stimulation of the protein kinase A (PKA) signalling pathway exerts an inhibitory effect on the proliferation of numerous cells, including T lymphocytes, In CD4(+) T helper cells, stimulation of PKA leads to suppression of interleukin 2 (IL-2) induction, while induction of the genes coding for the lymphokines IL-4 and IL-5 is enhanced, We show that the differential effect of PKA activity on induction of the IL-2 and IL-4 genes is mediated through their promoters, One major target of the suppressive effect of PKA is the kappa B site in the IL-2 promoter, A kappa B site is missing in the IL-4 promoter, Mutations preventing factor binding to the IL-2 kappa B site result in a loss of PKA-mediated suppression of IL-2 promoter activity, Furthermore, activation of the PKA signalling pathway impairs the inducible activity of multiple kappa B sites of the IL-2 promoter, but not of other factor binding sites, The reduction in activity of kappa B sites in activated and PKA-stimulated T cells is accompanied by changes in the concentration and DNA binding of Rel/NF-kappa B factors, Stimulation of the PKA pathway in Jurkat T cells with the PKA activator forskolin leads to an increase in synthesis of c-Rel and p105/p50, while synthesis of p65/RelA remains unchanged, However, nuclear translocation and DNA binding of p65 is distinctly impaired, probably due to a retarded degradation of I kappa B-alpha. In a similar way, stimulation of the PKA signalling pathway inhibits nuclear translocation of p65 and generation of nuclear kappa B complexes in peripheral T lymphocytes from murine lymph nodes, These results indicate that PKA-mediated suppression of NF-kappa B activity plays an important role in the control of activation of peripheral T lymphocytes.
引用
收藏
页码:1991 / 2004
页数:14
相关论文
共 95 条
[31]   PROTEIN KINASE-A ANTAGONIZES PLATELET-DERIVED GROWTH FACTOR-INDUCED SIGNALING BY MITOGEN-ACTIVATED PROTEIN-KINASE IN HUMAN ARTERIAL SMOOTH-MUSCLE CELLS [J].
GRAVES, LM ;
BORNFELDT, KE ;
RAINES, EW ;
POTTS, BC ;
MACDONALD, SG ;
ROSS, R ;
KREBS, EG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (21) :10300-10304
[32]  
GRILLI M, 1993, INT REV CYTOL, V143, P1
[33]  
HAFNER S, 1994, MOL CELL BIOL, V14, P6696
[34]  
HASLER F, 1983, J IMMUNOL, V131, P768
[35]   A DISTINCT MODULATING DOMAIN IN GLUCOCORTICOID RECEPTOR MONOMERS IN THE REPRESSION OF ACTIVITY OF THE TRANSCRIPTION FACTOR AP-1 [J].
HECK, S ;
KULLMANN, M ;
GAST, A ;
PONTA, H ;
RAHMSDORF, HJ ;
HERRLICH, P ;
CATO, ACB .
EMBO JOURNAL, 1994, 13 (17) :4087-4095
[36]   RAPID PROTEOLYSIS OF I-KAPPA-B-ALPHA IS NECESSARY FOR ACTIVATION OF TRANSCRIPTION FACTOR NF-KAPPA-B [J].
HENKEL, T ;
MACHLEIDT, T ;
ALKALAY, I ;
KRONKE, M ;
BEN-NERIAH, Y ;
BAEUERLE, PA .
NATURE, 1993, 365 (6442) :182-185
[37]   THE WEAK, FINE-TUNED BINDING OF UBIQUITOUS TRANSCRIPTION FACTORS TO THE IL-2 ENHANCER CONTRIBUTES TO ITS T-CELL-RESTRICTED ACTIVITY [J].
HENTSCH, B ;
MOUZAKI, A ;
PFEUFFER, I ;
RUNGGER, D ;
SERFLING, E .
NUCLEIC ACIDS RESEARCH, 1992, 20 (11) :2657-2665
[38]  
HORDIJK PL, 1994, J BIOL CHEM, V269, P3534
[39]   KAPPA-B SPECIFIC DNA-BINDING PROTEINS - ROLE IN THE REGULATION OF HUMAN INTERLEUKIN-2 GENE-EXPRESSION [J].
HOYOS, B ;
BALLARD, DW ;
BOHNLEIN, E ;
SIEKEVITZ, M ;
GREENE, WC .
SCIENCE, 1989, 244 (4903) :457-460
[40]   P21(RAS) COUPLES THE T-CELL ANTIGEN RECEPTOR TO EXTRACELLULAR SIGNAL-REGULATED KINASE-2 IN T-LYMPHOCYTES [J].
IZQUIERDO, M ;
LEEVERS, SJ ;
MARSHALL, CJ ;
CANTRELL, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (04) :1199-1208